BioRestorative Therapies Announces Reverse Stock Split Amid Nasdaq Delisting Fight
BRTX is trading near its 52-week low of $0.159 (0.4% above the low).
Summary
BioRestorative Therapies announced a reverse stock split, a move that follows a cascade of distress signals: CEO and CFO resignations in July, a product shipment halt in August, a Nasdaq delisting notice for late filing, and an auditor dismissal on September 1. The reverse split is aimed at regaining compliance with Nasdaq's minimum bid price requirement, but it does not address the underlying operational and governance turmoil. With the stock trading near its 52-week low at $0.16, the split will mechanically raise the share price but often signals financial weakness and can lead to further selling pressure. The board approved a 1-for-20 reverse split by unanimous written consent on August 27, 2026, and stockholder approval was not required under Nevada law. The split takes effect at 4:30 p.m. ET on September 7, 2026, with trading on a split-adjusted basis starting September 8 under new CUSIP 090655705 and the existing symbol BRTX. Authorized common shares will be reduced from 1.5 billion to 75 million, and issued and outstanding common shares will be reduced from 27,622,556 to approximately 1,381,128. Fractional shares will be rounded up to the nearest whole share, and outstanding stock options, warrants, equity awards, and the 2021 Stock Incentive Plan will be proportionately adjusted. The split will affect all holders uniformly and will not alter any holder's percentage ownership interest, except for de minimis changes from fractional share treatment. Investors should watch for any progress on the delayed 10-Q filing.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The reverse split takes effect at 4:30 p.m. ET on September 7, 2026, with trading on a split-adjusted basis starting September 8 under new CUSIP 090655705. Authorized common shares will be reduced from 1.5 billion to 75 million.
- Share Reduction — Issued and outstanding common shares will be reduced from 27,622,556 to approximately 1,381,128.
- Fractional Shares — Fractional shares will be rounded up to the nearest whole share, with TranShare Corporation authorized to effect rounding.
- Equity Adjustments — Outstanding stock options, warrants, equity awards, and the 2021 Stock Incentive Plan will be proportionately adjusted.
- Ownership Impact — The split will affect all holders uniformly and will not alter any holder's percentage ownership interest, except for de minimis changes from fractional share treatment.
- Trading Details — The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the opening of trading on September 8, 2026, under the existing symbol BRTX.
- Holder Instructions — Shares held in street name will be treated per the nominee's procedures; beneficial holders should contact their bank, broker, or nominee. TranShare will send instructions to record holders with certificates; book-entry or brokerage holders need take no action.
- Par Value — Common stock has a par value of $0.0001 per share.
- Filing — The Company filed a Certificate of Change with Nevada on September 2, 2026.
All 15 details
- Common stock has a par value of $0.0001 per share.
- Board approved the split by unanimous written consent on August 27, 2026.
- Stockholder approval was not required for the split under Nevada law.
- Issued and outstanding common shares will be reduced from 27,622,556 to approximately 1,381,128.
- Fractional shares will be rounded up to the nearest whole share.
- Outstanding stock options, warrants, equity awards, and the 2021 Stock Incentive Plan will be proportionately adjusted.
- The Company filed a Certificate of Change with Nevada on September 2, 2026.
- Shares held in street name through a bank, broker, or other nominee will be treated in accordance with the procedures of such bank, broker, or nominee, which may differ from the treatment of holders of record.
- Beneficial holders should contact their bank, broker, or nominee with any questions.
- The Reverse Stock Split will affect all holders of Common Stock uniformly and will not alter any holder’s percentage ownership interest in the Company, except for de minimis changes resulting from the treatment of fractional shares.
- The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the opening of trading on September 8, 2026.
- The Common Stock will trade under the existing trading symbol “BRTX”.
- TranShare Corporation, the Company’s transfer agent, is authorized to effect rounding for fractional shares on behalf of the Corporation.
- TranShare Corporation will send instructions to stockholders of record who hold stock certificates regarding the exchange of certificates for Common Stock.
- Stockholders who hold their shares of Common Stock in book-entry form or in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares of Common Stock following the Reverse Stock Split.
At the time of this announcement, BRTX was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.16 to $1.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.